Publication

The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.

Lallo, Alice
; 
Frese, Kristopher K
; 
Morrow, C
; 
Szczepaniak S
; 
Gulati, Sakshi
; 
Schenk, Maximilian W
; 
Trapani, F
; 
Simms, N
; 
Galvin, Melanie
; 
Brown, Stewart
... show 10 more
Citations
Altmetric:
Abstract
Introduced in 1987, platinum-based chemotherapy remains standard of care for small cell lung cancer, a most aggressive, recalcitrant tumor. Prominent barriers to progress are paucity of tumor tissue to identify drug targets and patient relevant models to interrogate novel therapies. Following our development of circulating tumour cell patient-derived explants (CDX) as models that faithfully mirror patient disease, here we exploit CDX to examine new therapeutic options for small cell lung cancer.
Authors
Lallo, Alice
Frese, Kristopher K
Morrow, C
Szczepaniak S
Gulati, Sakshi
Schenk, Maximilian W
Trapani, F
Simms, N
Galvin, Melanie
Brown, Stewart
Hodgkinson, Cassandra L
Priest, Lynsey
Hughes, A
Lai, Z
Cadogan, E
Khandelwal, Garima
Simpson, Kathryn L
Miller, Crispin J
Blackhall, Fiona H
O'Connor, M
Dive, Caroline
Affiliation
Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute
Description
Date
2018-06-25
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer. 2018, Clin Cancer Res
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/621136
Embedded videos